Compare Amphastar Pharmaceuticals Inc (AMPH) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Essex Property Trust, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Essex Property Trust, Inc. trades at $293.55 (market cap $18.86B). The key difference: Essex Property Trust, Inc. is far larger — about 22.8× Amphastar Pharmaceuticals Inc's market cap, and Essex Property Trust, Inc. pays a 3.53% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ESS | |
|---|---|---|
Market Cap | $826.08M | $18.86B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $298.33 |
52-Week Low | $16.87 | $239.61 |
Enterprise Value | $1.22B | $25.59B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
ESS trades at $293.55, up 0.83% on the day, with a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 30.03% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and the company's addition to the Russell Microcap Index, reflecting positive momentum.
The outlook for ESS is supported by strong West Coast rental demand and AI-driven employment growth, though risks include high debt levels and Seattle market weakness. Analyst consensus is mixed with a $292.89 price target, slightly below the current price, indicating cautious optimism amid valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
